Novus Therapeutics Announces Name Change to Eledon Pharmaceuticals; Provides Corporate Update and OutlookGlobeNewsWire • 01/04/21
Novus Therapeutics, Inc. (NVUS) CEO David-Alexandre Gros on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/17/20
Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16Business Wire • 11/10/20
Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral SclerosisBusiness Wire • 11/02/20
Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment ConferencesBusiness Wire • 09/15/20
Novus Therapeutics stock loses nearly half its value after disappointing drug trial resultsMarket Watch • 06/01/20